List view / Grid view
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…
US researchers have shown that CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity.
A new Drug Target Review issue is now ready to download! This issue features articles which explore how artificial intelligence can enhance screening and ways to find new hits through simultaneous orthogonal screens. Also included are articles on CRISPR, immuno-oncology and RSV vaccines.
Swedish researchers have discovered that by measuring immune cells in the cerebrospinal fluid when diagnosing ALS, it is possible to predict how fast the disease may progress.
US researchers find that bacteria could help tumours progress and resist treatment.
Pre-clinical experiments involving cells from ICUs patients infected by SARS-CoV-2, and mice infected by MHV-A59 (murine hepatitis virus A59) show promise in treating COVID-19.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
A new study has shown that lactate, a metabolic byproduct produced during exercise, could augment current cancer immunotherapies.
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
Researchers have discovered a way to ignite T cells, potentially increasing the scope and success of T cell-based immunotherapy.
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
Scientists have found that unconventional T cells migrate from tissue into the lymph nodes and influence immune responses there.
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma.
